NCT06245785Completed
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function: A Chinese Multicenter Observational Study
Source: ClinicalTrials.gov · Last updated 7 Feb 2024
Brief summary (registry, in English)
Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. Established practice guidelines for patients with HCC and impaired liver function are lacking. The treatment allocation in these populations is heterogeneous and remains controversial. This study compared the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in patients with HCC and impaired liver function.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2200 (actual)
- First submitted
- 30 Jan 2024
- Start date
- 1 Jan 2023
- Primary completion date
- 1 Apr 2023
- Lead sponsor
- Tang-Du Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06245785
What you commit to
- Study type: Observational
- Participants enrolled: 2200
- From 1 Jan 2023 to the primary completion date, 1 Apr 2023
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- （1） presence of portal vein tumour thrombosis (PVTT), hepatic artery, biliary duct or inferior vena cava invasion
- （6） other tumours or severe cardiac, cerebral, and renal insufficiency
Lab values
- （3） albumin-bilirubin grade 1 or 3
Other
- （2） extrahepatic spread (EHS)
- （4） Eastern Cooperative Oncology Group Performance Status (ECOG-PS) \>1
- （5） tumour number \>3
- （7）ascites, hepatic encephalopathy, and jaundice
Who the study is looking for
- patients with HCC who received conventional LR or TACE
Age in the registry: 18 years to - · Sex: All
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xijing hospital Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
| Tangdu Hospital Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.